Theravance Biopharma, Inc.

Historical 13F Holders

Symbol
TBPH
CUSIP
G8807B106
All holders as of
Q4 2024
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings
Period Filings Shares, Excl. Options Value, Excl. Options
2025 Q1 9 88.3 k $789 k
2024 Q4 130 44.9 M $422 M
2024 Q3 124 46.0 M $371 M
2024 Q2 137 47.8 M $406 M
2024 Q1 129 48.9 M $438 M
2023 Q4 127 49.4 M $555 M
2023 Q3 121 50.8 M $439 M
2023 Q2 128 52.8 M $546 M
2023 Q1 123 60.2 M $653 M
2022 Q4 133 63.6 M $713 M
2022 Q3 139 64.3 M $652 M
2022 Q2 119 64.4 M $583 M
2022 Q1 136 63.2 M $605 M
2021 Q4 128 59.7 M $660 M
2021 Q3 133 60.7 M $449 M
2021 Q2 114 60.8 M $883 M
2021 Q1 120 53.6 M $1.09 B
2020 Q4 113 53.5 M $952 M
2020 Q3 126 52.5 M $776 M
2020 Q2 131 53.0 M $1.11 B
2020 Q1 114 56.9 M $1.32 B
2019 Q4 114 45.4 M $1.18 B
2019 Q3 95 46.2 M $900 M
2019 Q2 116 48.9 M $799 M
2019 Q1 112 48.5 M $1.10 B
2018 Q4 99 48.2 M $1.23 B
2018 Q3 102 48.7 M $1.59 B
2018 Q2 92 47.9 M $1.09 B
2018 Q1 95 47.8 M $1.16 B
2017 Q4 86 46.9 M $1.31 B
2017 Q3 90 47.3 M $1.62 B
2017 Q2 96 46.3 M $1.84 B
2017 Q1 98 45.2 M $1.66 B
2016 Q4 102 43.9 M $1.40 B
2016 Q3 101 35.3 M $1.28 B
2016 Q2 98 33.9 M $770 M
2016 Q1 83 28.2 M $529 M
2015 Q4 88 27.7 M $453 M
2015 Q3 84 20.5 M $226 M
2015 Q2 90 22.4 M $292 M
2015 Q1 88 20.9 M $362 M
2014 Q4 95 20.8 M $310 M
2014 Q3 96 21.7 M $501 M
2014 Q2 97 20.7 M $659 M
2014 Q1 1 842 $14.6 k